X-Message-Number: 319
From att!garnet.berkeley.edu!quaife Tue May  7 01:01:09 PDT 1991
Date: Tue, 7 May 91 01:01:09 PDT
From: 
Message-Id: <>
To: 
Subject: cryonics mailing list

     TRANS TIME Sells Cryomedical Shares for $537,000 Profit

                     Art Quaife, President
                         TRANS TIME, INC.

Every dog has his day.  TRANS TIME just received a check for
$540,000 from Cryomedical Sciences, buying out the 540,000 shares
of their stock that we owned.  Cryomedical is a public company,
incorporated only 3.5 years ago as TRANS TIME MEDICAL PRODUCTS.  We
carried this stock on our books at $22,000, so this represents a
tidy $518,000 profit.  Add this to the $19,000 profit we made at
the end of last year in selling 20,000 shares, and we have $537,000
profit.

TRANS TIME believes that cryonic suspension is an extremely
valuable service, and the best mechanism for further developing it
is through the normal capital markets.  Our initial offering of
common stock was in 1975, for $10.00 per share.  Our current
offering is for $70.00 per share.  This is a 13.9% return on
investment, compounded yearly.  This is about the same as the rate
of growth of the S&P 500, with dividends reinvested, over the same
period.  That means it is better return than achieved by almost all
mutual funds over the same period.  And that is much better than
savings accounts or money-market funds have done.  Thus our initial
investors have done quite well, compared to the most readily
available alternative investments, in one very tough industry.

Our approach contrasts with the can-rattling approach of the non-
profit cryonics societies, who regularly beg for donations, which
approach I find hard to understand.  Why would anyone give away
$1000 to the can-rattler to further cryonics, when he could invest
the $1000 in a cryonics stock company, achieve a comparable
improvement of the state of the art, and next year have his
investment worth $1100?

Of course our stock is still not very liquid;  it is difficult to
sell.  But this will change within next few years, if TRANS TIME
goes public.  Meanwhile, our colleagues in BioTime are working on
repeating the Cryomedical story.  TRANS TIME is using $60,000 of
its Cryomedical profits to purchase some of BioTime's first
offering of stock.  Ours is one of the largest investments yet made
in BioTime.  TRANS TIME has the rights to use all the technology
and products BioTime develops, for cryonics purposes.  Their
financial promoters expect rapid growth in a market where some
biotechnology companies are raising tens of millions of dollars by
going public.  Since BioTime is now posturing itself as a
biotechnology research firm, rather than a cryonics firm, it should
be easier for them to attract widespread investment.  There has
also been discussion among financial promoters active in BioTime of
next trying to raise large amounts of investment money for TRANS
TIME, creating a public market for the stock.

To all our 85 shareholders, we offer our thanks for investing in a
company offering a service that so few have yet decided is
worthwhile.  Of course we know that many of you also wished to
further TRANS TIME as the company that might save your life.  We
think we have justified your confidence on both counts.

Meanwhile, our current issue of stock closes out on June 5, 1991.
If you are interested, write me right away at 10208 Pearmain St.,
Oakland CA 94603, for an Offering Notice.

Everything is coming up roses, in this best of all possible worlds
which continues to become better.

                                      Art Quaife, President

Rate This Message: http://www.cryonet.org/cgi-bin/rate.cgi?msg=319